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VectorT-cell-based cancer immunotherapy by the transfer of cloned TCRs that are isolated from tumor penetrat-
ing T-cells becomes a possibility through NY-ESOc259; a human-derived affinity-enhanced TCR that pro-
vides a level of sufficiency in long-term safety and efficacy. NY-ESOc259 recognizes a peptide common to
CTAs (LAGE-1 and NY-ESO-1) in melanoma. Risks associated with insertion related transformation in
gene therapy have been alleviated through strategies that include the engineering of transcription acti-
vator like effector nucleases (TALEN), RNA-guided nucleases (CRISPR/Cas9), Zinc-finger nucleases (ZFN).
Cancer immunotherapy based on the genetic modification of autologous T-cells (dependent on the engi-
neered autologous CD8+ T-cells), designed to distinguish and destroy cells bearing tumor-specific anti-
gens via a CAR is able to exterminate B-cell leukemias and lymphomas that are resilient to
conventional therapies. A tool with a very large reservoir of potentials in molecular therapy strategy is
the Pluripotent Stem Cells (PSC), with pluripotency factors that include Klf4, Sox2, c-Myc, Oct4, differen-
tiating into disease-associated cell phenotypes of three germ layers, comprising of mesoderm (e.g. cardiac
cells, blood and muscle), endoderm (liver, pancreas) and ectoderm (epidermis, neurons). It finds good
application in disease modelling as well as therapeutic options in the restoration of CGD by using
AAVS1 as the vector where the therapeutic cassette is integrated into the locus to restore superoxide pro-
duction in the granulocytes. Fascinatingly, Clinical trial involving iPSC are already underway where sci-
entists have plans to use iPSC-derived cells to treat macular degeneration (a devastating age-related eye
disease). Application of these findings has redefined incurable diseases disorders as curable.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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Gene therapy (gene replacement, gene editing, and gene inser-
tion) is a reality of one of the many potentials of molecular Biology.
A Clear understanding of the molecular mechanisms pivotal to cel-
lular mechanism is necessary for this modification of the blueprint
of life towards solving clinical and medical challenges. Though a lot
of credit goes to pharmacotherapy, it has not being without associ-
ated side effects or adverse reactions. Better sophisticated tools
(either new as well as refined or fine-tuned) viral and non-viral
vectors, naked oligonucleotides and plasmids have been developed
in recent times to solve the clinical challenges associated with gene
therapy. Lots of clinical trials have been initiated worldwide
(http://www.wiley.com//legacy/wileychi/genmed/clinical/). The
central focus of gene therapy is the insertion, deletion, editing/
modification of existing portion of the fundamental code (DNA)
in varied gene types (Table 1) to produce the desired gene expres-
sion outcome, generally targeted at preventing, treating or curing
disorders. Early gene therapy with an original focus on Orphan dis-
eases of damaging monogenetic defects that include primary
immunodeficiencies (PID), has greatly expanded to cover a number
of diverse disorders that now include heart failure, Parkinson’s dis-
ease, cancers, diabetes, other neurodegenerative and metabolic
disorders [1]. These limitations of pharmacotherapy notwithstand-
ing, gene therapy has associated limitations as well, and such
include the recognition of the protein on the viral capsid as an anti-
gen by the host immune system. This limitation has been improved
on through the more recently designed viral and non-viral vectors,
plasmids and RNAs for both in vivo and in vitro applications. The
pioneering motivation for the commencement of the gene therapy
trial to repair adenosine deaminase (ADA) deficiency was by using
genetically modified T-lymphocytes, creditable to Rosenberg et al.,
at NCI. Similarly, the first application of genes-modified
haematopoietic cells was performed via inserting a bacterial gene
into lymphocytes that have the potential of infiltrating cancerous
tumors, to track the associated behaviors of melanoma cells when
administered into the patients [2]. They are quite a number of suc-
cessful clinical trials that buttresses the fact that virtually a lot
more can also be done through the modification of T-cells suchTable 1
Gene types transferred in Gene therapy clinical trials in order of ascending percentage
hierarchy. Data Sourced from: (www.wiley.co.uk/genmed/clinical) on 2nd June, 2017.




Cell cycle 10 0.4
Hormone 10 0.4
Oncogene regulator 12 0.5
Adhesion molecule 12 0.5
Antisense 17 0.7
Cell protection/Drug resistance 20 0.8
Porins, ion channels, transporters 23 0.9
Transcription factor 35 1.4
Oncolytic virus 52 2.1
Marker 55 2.2
Unknown 63 2.6
Replication inhibitor 94 3.8
Suicide 173 7
Growth factor 176 7.1






Total 2463as the incorporation of chimeric antigen receptors (CAR) in order
to enhance tumor cell recognition towards facilitating a fleet of
cancer killing cells to the target. Gene therapy holds better pro-
mises for us in treating diseases such as hemoglobinopathies, can-
cer immunotherapies, ocular diseases, hemophilia B, neurological
diseases [3], immunological, neurodegenerative, hematological
and other metabolic disorders that have eluded the cure sought
through the conventional pharmacotherapy. Rapid gene therapy
improvements are recorded every year (Fig. 1). Different phases
of clinical trials (Table 2) are rapidly underway towards improving
on the molecular equipment for driving gene therapy to expecta-
tion. Progress in enhanced vector systems for ex vivo as well as
in vivo gene transfer have become a true potential for managing
various disease with increased range of medical application
beyond genetic disorders; redefining diseases previously classified
untreatable, curable. There is the need to get the medical and
research community updated on the very recent strides in gene
therapy through the use of modified T-cells (using TCR and CTAs),
Chimeric Antigen Receptor (CAR) and Other Molecular tools, there-
fore, the need for this study.2. Cancer immunotherapy using TCR and CTAs gene-modified
T-Cells
T-cell-based cancer immunotherapy by the transfer of cloned
TCRs that are isolated from tumor penetrating T-cells (engineered
ex vivo to convey their specificity to a specific tumor antigen)
becomes a possibility, already demonstrated by a number of gene
therapy trials. The engineered tumor-specific T cells are thereafter
re-administered to the beneficiary, where they identify tumor anti-
gen in HLAs context in the tumor microenvironment. A variety of
cancers including neuroblastoma, synovial cell sarcoma, colorectal
cancer and melanoma are treatable with genetically modified TCRs
with some level of associated adverse effects that results from off
targets [4–6]. Some of the side effects (including neurotoxicity)
could be alleviated by finding an alternative to TCRs in Cancer
testes antigens (CTAs; MAGE-A3). They are a group of tumor-
associated antigens with limited expression to male germ cells
(in the testis, trophoblasts, placenta, ovary on some occasions)
shared by several sorts of malignances such as bladder, breast,
lung, ovary, myeloma, melanoma and metastatic cancer [7,8].
These findings has been supported by a number of current clinical
studies with the accession code #NCT01352286; #NCT01350401;
#NCT01273181. The fatal adverse effect (mostly neurological) is
presumably associated with MAGE-A12 expression and MAGE-
A3-specific T-cell infusion [7]. Other adverse effects include severe
myocardial damage, raising grave safety concerns. Hope surfaces
as NY-ESOc259; a human-derived affinity-enhanced TCR provides
a level of sufficiency in long-term safety and efficacy on this
approach. NY-ESOc259 recognizes a peptide common to CTAs
(LAGE-1 and NY-ESO-1) in melanoma. This finding is supported
by clinical studies (#NCT01352286) [9].2.1. Targeted specific gene correction (amendment) strategies
Though a lot of risks associated with insertion related transfor-
mation in gene therapy have been alleviated through the engineer-
ing of various vectors, this strategy is not enough, and the
continuous input of efforts is necessary to further reduce this risk.
These strategies include the engineering of transcription activator
like effector nucleases (TALEN), RNA-guided nucleases (CRISPR/
Cas9), Zinc-finger nucleases (ZFN) [10–13]. To also achieve this,
other ultra-specific site-directed gene correction is employed,
and a typical example in the development of genetic scissors
via fusing DNA-binding domains unto the catalytic domain of
Fig. 1. The Number of Gene Therapy Clinical Trials Approved Worldwide before, and from 1989 to 2016, as updated in August 2016. Data Sourced from: (www.wiley.co.
uk/genmed/clinical) on 2nd June, 2017.
Table 2
Phases of Gene Therapy Clinical Trials. Data Sourced from: (www.wiley.co.uk/gen-
med/clinical) on 2nd June, 2017.
Clinical Trial Phase Number (n) Percentage (%)
Phase I 1409 57.20
Phase I/II 500 20.30
Phase II 429 17.40
Phase II/III 24 1
Phase III 93 3.80
Phase IV 3 0.10
Single subject 5 0.20
Total 2463 100
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specific locus) by taking advantage of the functional separation of
transcription factors resulting in a DNA-binding domain as well as
a transcription regulatory domain, thus recruiting the DNA repair
machinery to the specific site. An in-trans, homologous recombina-
tion will result in a specific genomic site integration of the endoge-
nous sequences by providing an exogenous DNAwith arms that are
homologous to the sequence adjacent to the DSB, which are
corrected by the non-homologous end-joining (NHEJ) repair
machinery that creates mutations at the DSB site. Although theoff-target genotoxicity along with cytotoxicity of the designer
nucleases are a major consideration that has to some extent,
delayed the translation of these experimental results to clinical
practice. In perspective, one great strategy of this area of gene ther-
apy in exploiting rationally designed single guide RNA is that it is
endowed with the ability to recruit corresponding nucleases to
any spot on the human genome, facilitating ‘vectorization’, provid-
ing site-directed integration of the therapeutic cassette into a
specific target locus (e.g. AAVS1 locus, located in between exon 1
and intron 1 phosphatase 1 regulatory subunit 12C gene), minimiz-
ing dysregulation of gene expression, while still protecting the cas-
sette from epigenetic effects [14]. Without any alterations in the
transcriptional behaviour of genes adjacent to the target gene,
Zinc-finger nucleases (ZFN)-mediated site-specific recombination
at such site produces a sustained transgene expression [15,16]. In
attempting to apply these findings in molecular therapy to treating
HIV-1 infection, over 30 HIV-patients have been cared for with
zinc-finger nuclease-modified T cells, in a multicentre clinical trial
initiated; focusing on specific gene disruption by a zinc-finger
nuclease to target the HIV-1 co-receptor CCR5 in order to protect
T cells from new infection, as prophylactic for this T cells which
are the main target of HIV-1 [17,18]. The mechanism involves a
disruption of CCR5 locus, which results in a sustained improve-
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maintenance of CCR5-modified central memory CD4 cells [19].
2.2. Immunotherapy based on chimeric antigen receptor (CAR)
Beyond genetic diseases lie an ocean of other non-genetic dis-
ease types treatable by gene therapy. Such an application is cancer
immunotherapy, which is based on the genetic modification of
autologous T-cells. It is effective in exterminating B-cell leukemias
and lymphomas resilient to conventional therapies. Themechanism
of the genetic modification of autologous T-cells is based on engi-
neered autologous CD8+ T-cells designed to distinguish and destroy
cells bearing tumor-specific antigens via a CAR. The great character-
istic advantage of the CAR is that it combines the specificity of mon-
oclonal antibody, cytotoxic and the proliferative abilities of
activated CD8+ T-cell. Different generations of CAR-modified autol-
ogous CD8+ T-cells developed with variations of signaling domains
have been created through ex vivo gene transfer using Lentiviral
Vector [20–22] expressing varied efficacy. Clinical trials employing
modified T cells have used CARs in correcting relapsed as well as B-
cell lymphoma, refractory B-cell leukemias, acute lymphoblastic
leukemia (ALL) (#NCT01044069) and chronic lymphocytic leuke-
mia (CLL) (#NCT00466531). As opposed to the advantage of lack
of cytokine release syndrome, and the rapid crowded motility of
19-28z+ T-cells to the locations of CD19+ tumor, these procedures
were not without setbacks such as p53 gene deletions, deficient
genetic prognosticmarkers, and displayed advanceddisorder as evi-
denced in bulky lymphadenopathy. Clinical observations
(#NCT01029366, #NCT00924326, #NCT01087294) from targeting
CAR T-cells (>1000-fold) containing a co-stimulatory domain from
CD137 (4-1BB) in addition to the T-cell receptor f-chain (CTL019)
with CD19 demonstrated potent non-cross-resistant activity pre-
ceding infusion in CLL [23], with persisting memory CAR+ T cells
that retained anti-CD19 effector functionality. The varied long term
positive feedback from these clinical trials such as reversible tran-
sient toxicities, rapid tumor eradication as well as lack of graft ver-
sus host disease has opened the door to extending these trials to
further trials (#NCT01029366, #NCT01593696, #NCT01044069
and #NCT01626495) involving the more hostile B-ALL, expressing
the CD19 antigen also [24–28]. The setbacks associated with some
of these trials only point to the need to improve on CARs that recog-
nize other tumor-associated antigens in B-cell lymphomas and leu-
kemias [29]. The transfer of T-cell receptor (TCR) genes to fusion
proteins into B cells or Treg presumably fosters clinical immune tol-
erance induction [30,31]. Likewise, CAR NK cells have been demon-
strated to be cytotoxic to B-cell leukemia, as well as transducing
CARs into FoxP3+ regulatory CD4+ T cells (Treg), leading to specific
immunosuppression [32–34]. CAR gene transfer to T and NK cells
also shows potential for generating immunity to virus [35]. Optimal
co-stimulatory signaling domains or suicide gene switches are very
viable options being considered for better safety strategies as well
as the arduous conditioning regimens in these treatment
approaches. Promisingly, CAR T-cell therapies could also be a viable
option for solid tumors, human immunodeficiency and other
malignancies.
2.3. Updates in Inducing Pluripotent Stem Cells
Though improved as well as more reliable protocols such as
engraftable HSC leading to transplantable cell types in which there
is an integration of the modification into their natural niches
in vivo exists; where autologous transplants compatible to the
recipient’s immune system are hoped for [36,37], other remarkable
efforts such as the use of iPSC which has the potential of expanding
our pool of molecular therapies and possibly offer fascinating per-
spectives for the management of various disorders must beacknowledged. One very important tool with a very large reservoir
of potentials in molecular therapy strategy is the Pluripotent Stem
Cells (PSC), with pluripotency factors that include Klf4, Sox2, c-
Myc, Oct4, which can be generated from any individual, with the
greatest potential of differentiating into disease-associated cell
phenotypes of three germ layers, comprising of mesoderm (e.g.
cardiac cells, blood and muscle), endoderm (liver, pancreas) and
ectoderm (epidermis, neurons). A lot of evidences have supported
the underlying mechanism that mature cells can be ‘repro-
grammed’ into immature PSC by nucleus transfer becoming
induced Pluripotent Stem Cells (iPSC; monoclonal in nature),
hence, disease specific iPSC (the differentiated mature progeny)
could be designed from patients’ somatic cells [38–42]. One of
the viable therapeutic options to treating causative genetic anoma-
lies in monogenetic disease-specific is the iPSC obtainable by using
strategies that include non-integrating (sleeping beauty trans-
poson) as well as integrating viral vectors (including retroviral vec-
tors), mRNA and protein delivery. Despite all the risks associated
with insertion associated transformation, a reasonable percentage
of an encoded transgene using lentivirus occur in safe harbour
which allows for a retained globin expression in b-thalassaemia
iPSC as well as their differentiated cell lines progeny [43]. A good
application of cell and gene therapy, highlighting the potential of
iPSC strategies in disease modelling as well as therapeutic options
is also reported in the restoration of CGD by using AAVS1 as the
vector where the therapeutic cassette is integrated into the locus
with the aim of restoring superoxide production in the granulo-
cytes which are derived from the targeted iPSC obtained through
homologous recombination design [44,45]. Fascinatingly, Clinical
trials involving iPSC are already underway, where scientists have
plans to use iPSC-derived cells to treat macular degeneration (a
devastating age-related eye disease) (http://www.nature.com/
news/stem-cells-cruise-toclinic-1.12511).3. Conclusion
Several gene therapy trials have confirmed the clinical benefits
of the application of molecular biology and biotechnology tools in
handling diseases or disorders that have proven elusive to cure
using the conventional pharmacotherapy. Interesting clinical
achievements in various diseases types have been recorded over
the last decade. Gene therapy has been remarkably applied to rare
diseases, and in other applications such as in tumor suppressors,
oncogene downregulation, vector-directed cell lysis, suicide genes,
ocular, inherited immunodeficiency disorders, congenital eye dis-
eases, hemophilia B, lipoprotein lipase (LPL) deficiency, muscle dis-
orders and other inherited neurological disorders. There have been
apparent ethical, scientific, and technological challenges militating
against gene therapy, however, a lot of efforts have been made to
facilitate the efficient translation of gene therapy into clinical prac-
tice. Recently and worthy to be noted is the application of modified
T-cells (using TCR and CTAs), Chimeric Antigen Receptor (CAR) and
other molecular biology tools in recent gene therapy. The applica-
tion of gene therapy to these disease areas has redefined diseases
previously classified as incurable as curable.Conflict of Interest
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